Sacituzumab Govitecan provides a TROP2-targeting antibody-drug conjugate (ADC) for cancer and oncology research and specifically combines a TROP2-directed monoclonal antibody with the topoisomerase I inhibitor payload SN-38, supporting targeted cytotoxicity and ADC studies.
Key Features and Benefits
- TROP2-Targeting ADC: Combines a TROP2-directed monoclonal antibody with the cytotoxic payload SN-38.
- SN-38 Payload: Contains SN-38, the active metabolite of irinotecan and a potent topoisomerase I inhibitor.
- TROP2 Recognition: Supports studies of TROP2 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a hydrolyzable linker designed to facilitate release of the SN-38 payload.
- Targeted Payload Delivery: Supports investigation of antibody-mediated SN-38 delivery to TROP2-expressing cancer cells.
- Topoisomerase I Inhibition: SN-38 disrupts DNA replication specifically through topoisomerase I inhibition, supporting cytotoxicity studies.
- ADC Research Platform: Enables investigation specifically of target engagement, cellular uptake, payload release, and ADC activity.
Applications
- TROP2-Positive Cancer Research: Supports studies involving tumors with TROP2 expression.
- Breast Cancer Research: Especially useful for investigating TROP2-targeted ADC strategies in breast cancer models, including triple-negative breast cancer.
- Urothelial Cancer Research: Supports investigation of TROP2-directed approaches in urothelial cancer models.
- ADC Research: Useful for studying antibody targeting, internalization, payload delivery, and cytotoxic activity.
- Targeted Cancer Research: Supports investigation of antibody-mediated SN-38 delivery to cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating TROP2-dependent binding, internalization, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of TROP2 targeting and SN-38-mediated topoisomerase I inhibition.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Sacituzumab Govitecan combines TROP2-directed antibody targeting with the topoisomerase I inhibitor SN-38 and specifically supports TROP2-positive cancer, breast cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
